
Ependion - A balancing act

Redeye updates its estimates for Ependion following the Q2 2024 report, which showed stronger sales but lower profitability. The near-term outlook remains uncertain, but the company is well-positioned for medium- to long-term success as the underlying markets recover. Ependion continues to invest significantly in new product development and strategic areas, while simultaneously maintaining good cost control.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Ependion - A balancing act](#)